Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

(2011) G P Aithal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)

(2011) Paul B. Watkins et al.   DRUG SAFETY

HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

(2011) Colin F. Spraggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

(2011) Janet S. Lee et al.   Pharmacogenetics and Genomics

Hyperbilirubinemia in Lapatinib Treated Patients Is Associated with Gilbert's SyndromeUGT1A1Polymorphism.

(2010) C. Spraggs et al.   CANCER RESEARCH

Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method

(2010) Don C. Rockey et al.   HEPATOLOGY

Pharmacogenetics of drug hypersensitivity

(2010) Elizabeth J Phillips et al.   PHARMACOGENOMICS

Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?

(2009) JR Senior   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY